By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

UCB Group 

Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: (32-2) 559-99-99 Fax: (32-2) 559-99-00


SEARCH JOBS








Company News
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016 5:52:37 AM
Syndax Expands Pipeline With Exclusive Worldwide License Agreement For UCB Group (UCBJF.PK)’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program 7/6/2016 8:05:34 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Tops Teriparatide in Phase III Osteoporosis Study 4/4/2016 6:13:48 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Shines in Phase III Osteoporosis Trial 3/21/2016 6:50:18 AM
U.S. FDA Approves UCB Group (UCBJF.PK)'s New Epilepsy Treatment, BRIVIACT, For Patients With Partial-Onset Seizures 2/22/2016 10:38:26 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Osteoporosis Drug Comes Through in Late-Stage Study 2/22/2016 6:09:40 AM
Merus Snags Three Cardiovascular Products from UCB Group (UCBJF.PK) in EUR 92 Million Deal 2/2/2016 6:08:49 AM
UCB Group (UCBJF.PK) Divests U.S. Generics Unit For $1.53 Billion 11/7/2014 5:53:40 AM
UCB Group (UCBJF.PK) Deploys IMS Health Nexxus Suite And Intelligent Cloud To Drive Commercial Productivity, Accelerate Time To Insight 10/22/2014 7:54:42 AM
New Indication For VIMPAT® (Lacosamide): UCB Group (UCBJF.PK)'s Anti-Epileptic Drug Approved By FDA As Monotherapy In The Treatment Of Patients With Partial-Onset Seizures 9/2/2014 11:37:51 AM
12345678910...
//-->